Epidermicin NI01 effective for drug-resistant skin infections
19 June 2026We are pleased to share the publication of a new peer-reviewed study in the Journal of Antimicrobial Chemotherapy – Antimicrobial…
We are pleased to share the publication of a new peer-reviewed study in the Journal of Antimicrobial Chemotherapy – Antimicrobial…
From 17th-22nd April, Mat and Vicky headed to Munich, Germany for ESCMID GLOBAL 2026
Last week, CSO Mat Upton and CEO Gordon Barker travelled to Basel, Switzerland for the BEAM Alliance 10th AMR meeting.…
On 14th December, CSO Mat Upton was invited to attend the Final Forum of the Saudi Biotechnology Accelerator (SBA) in…
Amprologix celebrates research excellence at the University of Plymouth as CSO Professor Mat Upton presents the Research Excellence Award to…
Mat Upton, CSO, presented new data at the 9th AMR conference in Basel on 25th February. It was suggested that probably half the global antimicrobial R&D activity was represented by attendees in the room. In a recent robust skin infection model with MRSA strain USA300, data demonstrate that a single daily dose of lead antibiotic […]
Amprologix will be attending the Investival Showcase in London on 18th November 2024 Amprologix will be attending the Investival Showcase in London on 18th November 2024. We look forward to meeting industry partners and investors who share our passion for developing new treatments to combat the rising global threat from antimicrobial resistance, including superbugs like MRSA and VRE. For […]
Amprologix files the first of a new series of patents protecting novel molecular structures for the treatment of bacterial infections. July 2024 Amprologix has filed its first patent in a series aimed at developing novel molecular structures for the treatment of bacterial infections. This significant milestone stems from discoveries made by Amprologix's proprietary AI “discovery […]
Innovate UK has awarded Amprologix £1M of Biomedical Catalyst funding to continue the Tobraderm project 1st March 2024 Amprologix is delighted to receive confirmation of its success in securing a £1M Biomedical Catalyst award from Innovate UK for its Tobraderm project. The project will advance the company’s NI01 lead compound through late-preclinical testing for common […]
